SRRK at a glance
Scholar Rock Holding Corp (SRRK, SEC CIK 1727196) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 27, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Scholar Rock Holding Corp (SRRK) reported revenue of $0 and a net loss of $377.9 million. Diluted EPS was -$3.29.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Scholar Rock Holding Corp (SRRK) shares worth $1.8 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by AKKARAJU SRINIVAS on October 26, 2026 of 48,988 shares at $41.59 per share.
- In the last 90 days, SRRK insiders reported 6 open-market purchases ($12.0M) and 0 open-market sales ($0) on Form 4, a net purchase of $12.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 6 buys · 0 sells
- Net +$12.0M
- 13F holders
- 31 funds
- $1.8B · −2 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 1.01 · Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical company developing selective monoclonal antibodies targeting latent growth factors for rare neuromuscular diseases
- New products emphasized: Apitegromab subcutaneous formulation and SRK-439 anti-latent myostatin antibody, both in clinical development in 2026
- Strategic shift: Transitioning to global commercial-stage biotech; appointed new CEO and expanded U.S./European commercial teams (~50 employees)
- Notable metric: Submitted BLA for apitegromab in SMA in Jan 2025; received FDA Priority Review and EMA MAA acceptance in March 2025
- Unique fact: Apitegromab is first myostatin inhibitor with positive Phase 3 SAPPHIRE study outcome and plans to target additional indications including infants under 2 years and FSHD
Risk Factors
- FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization
- Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site
- Supply chain risk: reliance on limited third-party manufacturers for materials, with potential interruptions or quality issues impacting clinical/commercial supplies
- Competitive risk: dependence on continued availability of approved SMN-targeted treatments (e.g., nusinersen, risdiplam) for apitegromab trials; limited access could halt trials
- Financial risk: ongoing net losses and urgent need for additional capital to fund development and commercialization of apitegromab, SRK-181, SRK-439
Management Discussion & Analysis
- Net loss $377.9M in 2025 vs $246.3M in 2024, operating expenses up 52.6% to $384.6M from $252.1M
- R&D expense $208.4M (+12.9%), G&A expense $176.2M (+161.0%), driven by commercial launch prep for apitegromab
- Apitegromab R&D costs rose 14.7% to $89.8M; SRK-181 decreased 75.8%, SRK-439 decreased 22.9%
- Cash, cash equivalents, and securities $367.6M at 2025 YE, down $69.7M YoY; net cash used in operations $300.0M
- Raised $91.7M from ATM stock sales, $50M from debt facility, $63.8M from warrant exercises in 2025
- FDA CRL for apitegromab due to third-party fill-finish issues; resubmission pending resolution, Phase 2 trial in FSHD planned mid-2026
- Management expects ongoing substantial expenses for R&D, commercialization, and infrastructure build ahead of potential apitegromab launch
AI summary of the SRRK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added commercialization risk: FDA approved ISEMBYLD on September 11, 2026, making U.S. launch execution critical to revenue and profitability
- Most material regulatory update: third-party fill-finish facility received OAI classifications in 2025 and 2026, delaying EU approval and forcing MAA resubmission
- Regulatory pricing risk: CMS finalized GLOBE on October 2, 2026, requiring incremental Medicare Part B rebates beginning January 1, 2027
- Near-term operational risk: single-source apitegromab drug substance and fill-finish suppliers expose commercial supply to disruptions and batch failures
- Financial risk: ongoing net losses and additional capital requirements remain necessary to fund ISEMBYLD commercialization and pipeline development
Management Discussion & Analysis
- Q3 revenue $0.6M from ISEMBYLD, versus $0 in Q3 2025
- Gross margin approximately 98.7%, based on $0.6M revenue and $8,000 cost of revenue
- Best-performing program SRK-439 R&D costs $2.9M, up 77.4% YoY; apitegromab costs $20.0M, down 6.5%
- Cash, equivalents and marketable securities $413.6M, up $46.0M from December 31, 2025
- Operating cash use $234.2M; financing provided $280.0M, including $160.8M ATM proceeds and $197.7M debt proceeds
AI summary of the SRRK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $205 million cash proceeds from sale of Rare Pediatric Disease Priority Review Voucher to BioNTech
- Voucher awarded after FDA approval of ISEMBYLD on September 11, 2026
Item 2.02: Results of Operations and Financial Condition
- Press release covers Scholar Rock’s financial and operating results for the quarter ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1, the company’s earnings release
Item 7.01: Regulation FD Disclosure
- Conference call scheduled for November 10, 2026 at 8:00 a.m. ET
- Slides cover financial and operating results for quarter ended September 30, 2026
Item EX-99.1: Item EX-99.1
- ISEMBYLD U.S. launch underway, generating $0.6 million Q3 revenue after September 11 FDA approval
- Early demand broad across physicians and patients, but sustained treatment, reimbursement and market adoption remain key execution risks
Item EX-99.2: Item EX-99.2
- Q3 2026 earnings update: ISEMBYLD U.S. launch underway, with initial inventory shipments generating $0.6 million
- Early commercial reach: over one-third of Top 140 SMA centers prescribing, with demand across children and adults
Item 7.01: Regulation FD Disclosure
- FDA approved ISEMBYLD for spinal muscular atrophy patients aged 2 and older receiving SMN2-targeted treatment
- Management corrected prior statement: FDA requires a pregnancy safety study covering complications and birth outcomes
Item 8.01: Other Events
- FDA approval of ISEMBYLD™ (apitegromab-mstn) for spinal muscular atrophy
- Label covers adults and children aged 2 years and older receiving survival SMN2-targeted treatment
Item EX-99.1: Item EX-99.1
- FDA approval transforms Scholar Rock into a commercial-stage company with ISEMBYLD for SMA patients ≥2 years receiving SMN2-targeted therapy
- Phase 3 SAPPHIRE showed 2.2-point HFMSE improvement versus placebo at 10 mg/kg, with nominal p=0.0121
Item 7.01: Regulation FD Disclosure
- FDA approval of ISEMBYLD for SMA patients ages 2 and older receiving SMN2-targeted treatment
- Commercial launch opportunity in SMA, expanding Scholar Rock’s potential revenue base
Item EX-99.2: Item EX-99.2
- FDA-approved ISEMBYLD launch underway for SMA patients aged 2 and older receiving SMN2-targeted treatment
- Phase 3 showed 2.2-point HFMSE improvement versus placebo, supporting differentiated motor-function benefit
AI summaries of SRRK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SRRK
Don't miss the next SRRK filing
- Alerts as it files. A push when SRRK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SRRK, by share count.
- Ask anything. An AI agent that reads every SRRK filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Buy | Oct 26, 2026 | 48,988 | $41.59 |
| AKKARAJU SRINIVAS | Buy | Oct 26, 2026 | 97,982 | $41.59 |
| AKKARAJU SRINIVAS | Buy | Oct 23, 2026 | 94,000 | $41.31 |
| AKKARAJU SRINIVAS | Buy | Oct 23, 2026 | 500 | $41.82 |
| AKKARAJU SRINIVAS | Buy | Oct 23, 2026 | 1,000 | $41.82 |
| AKKARAJU SRINIVAS | Buy | Oct 23, 2026 | 47,000 | $41.31 |
| Woods Keith | G | Sep 24, 2026 | 48,034 | - |
| Hallal David | G | Sep 21, 2026 | 36,652 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | - | $0 |
| Operating Income | -$171.3M | -$252.1M | -$384.6M |
| Net Income | -$165.8M | -$246.3M | -$377.9M |
| Balance Sheet | |||
| Total Assets | - | $474.9M | $404.3M |
| Equity | $225.2M | $368.6M | $245.5M |
| ROE | -73.6% | -66.8% | -154.0% |
| Per Share | |||
| EPS | $-1.99 | $-2.47 | $-3.29 |
| Cash Flow | |||
| Operating CF | - | -$200.9M | -$300.0M |
| CapEx | $71K | $98K | $602K |
Source: XBRL data in Scholar Rock Holding Corp (SRRK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SRRK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $1.83B |
| Q2 2026 | 33 | $2.91B |
| Q1 2026 | 29 | $2.24B |
| Q4 2025 | 26 | $1.93B |
| Q3 2025 | 27 | $1.59B |
| Q2 2025 | 29 | $1.54B |
| Q1 2025 | 26 | $899.5M |
| Q4 2024 | 23 | $1.11B |
- Vanguard Portfolio Management LLC+1.96M (+190%)
- Citadel Advisors LLC+1.76M (+531%)
- Goldman Sachs Group+550.5K (+39%)
- Morgan Stanley+215.5K (+14%)
- Franklin Resources+110.4K (+13%)
- T. Rowe Price Group−929.3K (-14%)
- State Street Corp−353.3K (-7%)
- Raymond James Financial−129.4K (-54%)
- D.E. Shaw & Co−90.9K (-37%)
- Citigroup−65.8K (-58%)
- FMR LLC (Fidelity)−18.00M
- Two Sigma Investments−9.5K
- Blackstone Group−9.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SRRK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 27, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
SRRK SEC filings: frequently asked questions
Are SRRK insiders buying or selling?
In the last 90 days, Scholar Rock Holding Corp (SRRK) officers, directors and 10% owners reported 6 open-market purchases worth $12.0 million by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SRRK stock?
As of September 30, 2026, the largest Scholar Rock Holding Corp (SRRK) holders among the 13F filers tracked by SignalX were BlackRock ($461.9 million), T. Rowe Price Group ($283.4 million), Vanguard Capital Management LLC ($232.2 million), State Street Corp ($211.4 million), Vanguard Portfolio Management LLC ($144.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SRRK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Scholar Rock Holding Corp (SRRK) reported revenue of $0 and a net loss of $377.9 million. Diluted EPS was -$3.29. The figures come from the XBRL data in the 10-K.
What are the main risks in SRRK's latest 10-K?
In the 10-K filed March 3, 2026, Scholar Rock Holding Corp (SRRK) flagged: FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization. Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site. (AI summary of the Risk Factors section.)
What did SRRK report in its latest 8-K?
Scholar Rock Holding Corp (SRRK) filed an 8-K on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). $205 million cash proceeds from sale of Rare Pediatric Disease Priority Review Voucher to BioNTech.
What are the latest SRRK SEC filings?
Scholar Rock Holding Corp (SRRK) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 27, 2026.
What is SRRK's SEC CIK number?
Scholar Rock Holding Corp (SRRK)'s SEC Central Index Key (CIK) is 1727196. EDGAR lists every SRRK filing under that number.
Ask anything about SRRK
The research agent reads SRRK's filings, financials, insider trades and 13F holders, then answers with sources.